Login to Your Account



Pharma: Clinic Roundup


Tuesday, July 16, 2013
• Merck & Co. Inc., of Whitehouse Station, N.J., presented results from a Phase Ib study of MK-8931 in Alzheimer's disease at the Alzheimer's Association International Conference in Boston, showing a dose-dependent decrease in beta amyloid levels in cerebral spinal fluid following administration of the drug in patients with mild to moderate disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription